Protein and host factors implicated in the pathogenesis of light chain amyloidosis (AL amyloidosis)

References

• Osserman E F, Takatsuki K, Talal N. Multiple myeloma. I. The pathogenesis of “amyloidosis.”. Semin Hematol 1964; 1: 3–86
   PubMed Web of Science ®Google Scholar
• Isobe T, Osserman E F. Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Engl J Med 1974; 290: 473–477
   PubMed Web of Science ®Google Scholar
• Glenner G G. Amyloid deposits and amyioidosis: The ß-fibrilloses. NEngl J Med 1980; 302: 1283–1292; 1333–1343
   PubMed Web of Science ®Google Scholar
• Klafki H-W, Kratzin H D, Pick A I, Eckart K, Karas M, Hilschmann N. Complete amino acid sequence determinations demonstrate identity of the urinary Bence Jones protein (BJP-DIA) and the amyloid fibril protein (AL-DIA) in a case of AL-amyloidosis. Biochemistry 1992; 31: 3265–3272
   PubMed Web of Science ®Google Scholar
• Rabat E H, Wu T T, Perry H M, Gottesman K S, Foeller C. Sequences of Proteins of Immunological Interest, 5th edition. U.S. Department of Health and Human Services, PHS, NIH. 1991; volume 1
   Google Scholar
• Nyquist J, Ramstad H M, Sletten K, Husby G, Westermark P. Structural studies of two carbohydrate-containing immunoglobulin-kappa-light chain amyloid fibril-proteins of the variable subgroup I. AmyloidandAmyloidosis, R Kisilevsky, M D Benson, B Frangione, J Gauldie, T J Muckle, I D Young. Parthenon Publishing, New York 1994; 247–249, 1993
   Google Scholar
• Stewart A K, Schwartz R S. Immunoglobulin V regions and the B cell. Blood 1994; 83: 1717–1730
   PubMed Web of Science ®Google Scholar
• Klein R, Jaenichen R, Zachau H G. Expressed human immunoglobulin k genes and their hypermutation. EurJ Immunol 1993; 23: 3248–3271
   PubMed Web of Science ®Google Scholar
• Frippiat J-P, Lefranc M-P. Genomic organisation of 34 kb of the human immunoglobulin lambda locus (IGLV): Restriction map and sequences of new VIII genes. Mol Immunol 1994; 31: 657–670
   PubMed Web of Science ®Google Scholar
• Bauer T R, Jr., Blomberg B. The human L chain Ig locus. Recharacterization of JC6 and identification of a functional JC7. J Immunol 1991; 146: 2813–2820
   Google Scholar
• Hieter P A, Maizel J V, Jr, Leder P. Evolution of human immunoglobulin K J region genes. J Biol Chem 1982; 257: 1516–1522
   PubMed Web of Science ®Google Scholar
• Lafaille J J, DeCloux A, Bonneville M, Takagaki Y, Tonegawa S. Junctional sequences of T cell receptor γ genes: Implications for γ T cell lineages and for a novel intermediate of V-(D)-J joining. Cell 1989; 59: 859–870
   PubMed Web of Science ®Google Scholar
• Victor K D, Capra J D. An apparently common mechanism of generating antibody diversity: Length variation of the VL-JL junction. Mol Immunol 1994; 31: 39–46
   PubMed Web of Science ®Google Scholar
• Solomon A. Clinical implications of monoclonal light chains. Semin Oncol 1986; 13: 341–349
   PubMed Web of Science ®Google Scholar
• Bernier G M, Putnam F W. Monomer-dimer forms of Bence Jones proteins. Nature 1963; 200: 223–225
   Google Scholar
• Solomon A, Frangione B, Franklin E C. Preferential expression of human -light-chain variable-region subgroups in multiple myeloma, AL amyloidosis and Waldenström's macroglobulinemia. Clin Immunol Immunopathol 1982; 71: 183–189, Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V17 Ozaki S, Abe M, Wolfenbarger D, Weiss DT and Solomon A (1994)
   Google Scholar
• Bookchin R M, Nagel R L. Interactions between human hemoglobins: Sickling and related phenomena. Semin Hematol 1974; 11: 577–595
   PubMedGoogle Scholar
• Stevens F J, Solomon A, Schiffer M. Bence Jones proteins: A powerful tool for the fundamental study of protein chemistry and pathophysiology. Biochemistry 1991; 30: 6803–6805
   PubMed Web of Science ®Google Scholar
• Stevens F J, Myatt E A, Chang C-H, Westholm F A, Eulitz M, Weiss D T, Murphy C, Solomon A, Schiffer M. A molecular model for self-assembly of amyloid fibrils: Immunoglobulin light chains. Biochemistry 1995; 34: 10697–10702
   PubMed Web of Science ®Google Scholar
• Myatt E A, Westholm F A, Weiss D T, Solomon A, Schiffer M, Stevens F J. Pathogenic potential of human monoclonal immunoglobulin light chains: Relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci USA 1994; 91: 3034–3038
   PubMed Web of Science ®Google Scholar
• Hurle M R, Helms L R, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994; 91: 5446–5450
   PubMed Web of Science ®Google Scholar
• Kelly J W, Lansbury P T, Jr. A chemical approach to elucidate the mechanism of transthyretin and 6-protein amyloid fibril formation. Amyloid: Int J Exp Clin Invest 1994; 1: 186–205
   Web of Science ®Google Scholar
• Epp O, Lattman E E, Schiffer M, Huber R, Palm W. The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0–Å resolution. Biochemistry 1975; 14: 4943–4952
   PubMed Web of Science ®Google Scholar
• Wilkins Stevens P, Raffen R, Hanson D K, Deng Y-L, Berrios-Hammond M, Westholm F A, Murphy C, Eulitz M, Wetzel R, Solomon A, Schiffer M, Stevens F J. Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci 1995; 4: 421–432
   PubMed Web of Science ®Google Scholar
• Schormann N, Murrell J R, Liepnieks J J, Benson M D. Tertiary structure of an amyloid immunoglobulin light chain protein: A proposed model for amyloid fibril formation. Proc Natl Acad Sci USA 1995; 92: 9490–9494
   PubMed Web of Science ®Google Scholar
• Terry W D, Page D L, Kimura S, Isobe T, Osserman E F, Glenner G G. Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis. J Clin Invest 1973; 52: 1276–1281
   PubMed Web of Science ®Google Scholar
• Buxbaum J. Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture. J Clin Invest 1986; 78: 798–806
   Google Scholar
• Preud'homme J L, Ganeval D, Griinfeld J P, Striker L, Brouet J C. Immunoglobulin synthesis in primary and myeloma amyloidosis. Clin Exp Immunol 1988; 73: 389–394
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss D T. AL amyloidosis. Amyloid and Amyloidosis, 1993, R Kisilevsky, M D Benson, B Frangione, J Gauldie, T J Muckle, I D Young. Parthenon Publishing, New York 1994; 200–205
   Google Scholar
• Glenner G G, Ein D, Eanes E D, Bladen H A, Terry W, Page D L. Creation of “amyloid” fibrils from Bence Jones proteins in vitro. Science 1971; 174: 712–714
   PubMed Web of Science ®Google Scholar
• Linke R P, Tischendorf F W, Zucker-Franklin D, Franklin E C. The formation of amyloid-like fibrils in vitro from Bence Jones proteins of the VI subclass. J Immunol 1973; 111: 24–26
   PubMed Web of Science ®Google Scholar
• Glenner G G, Eanes E D, Bladen H A, Linke R P, Termine J D. ß-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J Histochem Cytochem 1974; 22: 1141–1158
   PubMed Web of Science ®Google Scholar
• Epstein W V, Tan M, Wood I S. Formation of “amyloid” fibrils in vitro by action of human kidney lysosomal enzymes on Bence Jones proteins. J Lab Clin Med 1974; 84: 107–110
   PubMed Web of Science ®Google Scholar
• Solomon A, McLaughlin C L. Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J Biol Chem 1969; 244: 3393–3404
   PubMed Web of Science ®Google Scholar
• Eulitz M, Linke R. Amyloid fibrils derived from V-region together with C-region fragments from a II-immunoglobulin light chain (HAR). Biol Chem Hoppe-Seyler 1985; 366: 907–915
   PubMed Web of Science ®Google Scholar
• Eulitz M, Breuer M, Linke R P. Is the formation of AL-type amyloid promoted by structural peculiarities of immunoglobulin L-chains?. Biol Chem Hoppe-Seyler 1987; 368: 863–870
   PubMedGoogle Scholar
• Eulitz M, Breuer M, Eblen A, Weiss D T, Solomon A. Production of amyloidogenic peptides from human immunoglobulin light (L)-chains. Amyloid and Amyloidosis 1990, J B Natvig, Ø Førre, G Husby, A Husebekk, B Skogen, K Sletten, P Westermark. Kluwer Academic Publishers, DordrechtThe Netherlands 1990; 505–510
   Google Scholar
• Castaño E M, Ghiso J, Prelli F, Gorevic P D, Migheli A., Frangione B. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease ß-protein. Biochem Biophys Res Commun 1986; 141: 782–789
   PubMed Web of Science ®Google Scholar
• Gorevic P D, Castaño E M, Sarma R, Frangione B. Ten to fourteen residue peptides of Alzheimer's disease are sufficient for amyloid fibril formation and its characteristic Xray diffraction pattern. Biochem Biophys Res Commun 1987; 147: 854–862
   PubMed Web of Science ®Google Scholar
• Kirschner D A, Inouye H, Duffy L K, Sinclair A, Lind M, Selkoe D J. Synthetic peptide homologous to ß protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 1987; 84: 6953–6957
   PubMed Web of Science ®Google Scholar
• Westermark P, Engström U, Johnson K H, Westermark G T, Betsholtz C. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990; 87: 5036–5040
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Prelli F, Verga L, Giaccone G, Sarma R, Gorevic P, Ghetti B, Passerini F, Ghiboudi E, Forloni G, Salmona M, Bugiani O, Frangione B. Synthetic peptides homologous to prion protein residues 106–147 form amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 1993; 90: 9678–9682
   PubMed Web of Science ®Google Scholar
• Paul S, Li L, Kalaga R, Wilkins-Stevens P, Stevens F J, Solomon A. Amyloid fibril formation requires a chemically discriminating nucleation event: Studies of an amyloidogenic sequence from the bacterial protein Osm B. Biochemistry 1995; 31: 12345–12352, Natural catalytic antibodies: Peptide-hydrolyzing activities of Bence Jones proteins and V45 Jarrett JT and Lansbury PT Jr (1992)
   Google Scholar
• Jarrett J T, Lansbury P T, Jr. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993; 73: 1055–1058
   PubMed Web of Science ®Google Scholar
• Jarrett J T, Berger E P, Lansbury P T, Jr. The carboxy terminus of the ß amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993; 32: 4693–4697
   PubMed Web of Science ®Google Scholar
• Come J H, Fraser P E, Lansbury P T, Jr. A kinetic model for amyloid formation in the prion diseases: Importance of seeding. Proc Natl Acad Sci USA 1993; 90: 5959–5963
   PubMed Web of Science ®Google Scholar
• Niewold T A, Hoi P R, van Andel A CJ, Lutz E TG, Grays E. Enhancement of amyloid induction by amyloid fibril fragments in hamster. Lab Invest 1987; 56: 544–549
   PubMed Web of Science ®Google Scholar
• Cathcart E S. AEF: An enigma wrapped in a mystery. Amyloid: Int J Exp Clin Invest 1995; 2: 126–127
   Web of Science ®Google Scholar
• Niewold Th A, Grays E, Kisilevsky R, Shirahama T S. Fibril amyloid enhancing factor (FAEF)-accelerated amyloidosis in the hamster is not dependent on serine esterase activity and mononuclear phagocytosis. Scand J Immunol 1991; 34: 101–107
   PubMed Web of Science ®Google Scholar
• Varga J, Flinn M SM, Shirahama T, Rodgers O G, Cohen A S. The induction of accelerated murine amyloid with human splenic extract. Virchows Arch [B] 1986; 51: 177–185
   Google Scholar
• Ali-Khan Z I, Quirion R, Rabitaille Y, Alizadeh-Khiavi K., Du T. Evidence for amyloid enhancing factor in Alzheimer brain extract. Acta Neuropathol 1988; 77: 82–90
   PubMed Web of Science ®Google Scholar
• Eriksson S, Janciauskiene S, Lannfelt L. Solubilization of ß-amyloid-(l-42)-peptide: Reversing the ß-sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci USA 1995; 92: 369–371, α55 Fasman GD, Perczel Aand Moore CD (1995)
   Google Scholar
• Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone M G, Garini P, Diegoli M, Trizio D, Ballinari D. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995; 92: 2959–2963
   PubMed Web of Science ®Google Scholar
• Gianni L, Bellotti V, Gianni A M, Merlini G. New drug therapy of amyloidoses: Resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorabicin. Blood 1995; 86: 855–861
   PubMed Web of Science ®Google Scholar
• Sanders P W, Herrera G A, Kirk K A, Old C W, Galla J H. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991; 64: 527–537
   PubMed Web of Science ®Google Scholar
• Ganeval D, Noël L-H, Preud'homme J-L, Droz D, Grünfeld J-P. Light-chain deposition disease: Its relation with AL-type amyloidosis. Kidney Int 1984; 26: 1–9
   PubMed Web of Science ®Google Scholar
• Jacquot C, Saint-Andre J-P, Touchard G, Nochy D, D' Auzac de Lamartinie C, Oriol R, Draet P, Bariety J. Association of systemic light-chain deposition disease and amyloidosis: A report of three patients with renal involvement. Clin Nephrol 1985; 24: 93–98
   PubMed Web of Science ®Google Scholar
• Troussard X, de Ligny B H, Gallet B, Ganeval D, Mandard J-C, Ryckelynck J-P, Leporrier M. Massive systemic amyloidosis associated with light-chain deposition disease. Nephron 1989; 52: 139–143
   PubMedGoogle Scholar
• Buxbaum J N, Chuba J V, Hellman G C, Solomon A, Gallo G R. Monoclonal immunoglobulin deposition disease: Light chain and heavy chain deposition diseases and their relation to light chain amyloidosis. Ann Intern Med 1990; 112: 455–464
   PubMed Web of Science ®Google Scholar
• Chang C-H, Short M T, Westholm F A, Stevens F J, Wang B-C, Furey W, Jr, Solomon A, Schiffer M. Novel arrangement of immunoglobulin variable domains: X-ray crystallographic analysis of the Δ-chain dimer Bence-Jones protein Loc. Biochemistry 1985; 24: 4890–4897
   Google Scholar
• Sanders P W, Herrera G A, Galla J H. Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo. Kidney Int 1987; 32: 851–861
   PubMed Web of Science ®Google Scholar
• Sanders P W, Booker B B, Bishop J B, Cheung H C. Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990; 85: 570–576
   PubMed Web of Science ®Google Scholar
• Sanders P W, Booker B B. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89: 630–639
   PubMed Web of Science ®Google Scholar
• Baltz M L, Caspi D, Evans D J, Rowe I F, Hind C RK, Pepys M B. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66: 691–700
   PubMedGoogle Scholar
• Nelson S T, Lyon M, Gallagher J T, Johnson E A, Pepys M B. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. Biochem J 1991; 275: 67–73
   PubMed Web of Science ®Google Scholar
• Stenstad T, Magnus J H, Husby G, Kolset S O. Purification of amyloid-associated heparan sulphate proteoglycans and galactosaminoglycan free chains from human tissues. Scand J Immunol 1993; 37: 227–235
   PubMed Web of Science ®Google Scholar
• Snow A D, Willner J, Kisilevsky R. Sulphated glycosaminoglycans: A common constituent of all amyloid?. Lab Invest 1987; 56: 120–124
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Frangione B. Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 1992; 135: 235–238
   PubMed Web of Science ®Google Scholar
• Gallo G, Wisniewski T, Choi-Miura N-H, Ghiso J, Frangione B. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145: 526–530
   PubMed Web of Science ®Google Scholar
• Frangione B, Wisniewski T, Ghiso J. Chaperoning Alzheimer's amyloids. Neurobiol Aging 1994; 15: S97–S99
   Google Scholar
• Klafki H, Pick A I, Pardowitz I, Cole T, Awni L A, Barnikol H, Mayer F, Kratzin H D, Hilschmann N. Reduction of disulfide bonds in an amyloidogenic Bence Jones protein leads to formation of “amyloid-like” fibrils in vitro. Biol Chem Hoppe-Seyler 1993; 374: 1117–1122
   Google Scholar
• Tennent G A, Lovat L B, Pepys M B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92: 4299–4303
   PubMed Web of Science ®Google Scholar
• Solomon A, Waldmann T A, Fahey J L, McFarlane A S. Metabolism of Bence Jones proteins. J Clin Invest 1964; 43: 103–117
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Perfetti V, Bellotti V, Garini P, Zorzoli I, Rovati B, Marinone M G, Ippoliti G, Merlini G. AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies. Lab Invest 1994; 71: 853–861
   Google Scholar
• Miura K, Shirasawa H. Lambda III subgroup immunoglobulin light chains are precursor proteins of nodular pulmonary amyloidosis. Am J Clin Pathol 1993; 100: 561–566
   PubMed Web of Science ®Google Scholar
• Batuman V, Dreisbach A W, Cyran J. Light-chain binding sites on renal brush-border membranes. Am J Physiol 1990; 258: F1259–F1265
   Google Scholar
• Hendershot L M. Immunoglobulin heavy chain and binding protein complexes are dissociated in vivo by light chain addition. J Cell Biol 1990; 111: 829–837
   PubMedGoogle Scholar
• Haas I G. BiP-A heat shock protein involved in immunoglobulin chain assembly. Curr Top Microbiol Immunol 1991; 167: 71–82
   Google Scholar
• Stone M J. Amyloidosis: A final common pathway for protein deposition in tissues. Blood 1990; 75: 531–545
   PubMed Web of Science ®Google Scholar
• Durie B GM, Persky B, Soehnlen B J, Grogan T M, Salmon S E. Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 1982; 307: 1689–1692
   PubMed Web of Science ®Google Scholar
• Franklin E C, Pras M. Immunologic studies of water-soluble amyloid fibrils. Comparative studies of eight amyloid preparations. J Exp Med 1969; 130: 797–808
   PubMed Web of Science ®Google Scholar
• Benson M, Skinner M, Cohen A S. Antigenicity and cross-reactivity of denatured fibril proteins of primary, secondary and myeloma associated amyloids. J Lab Clin Med 1975; 85: 650–659
   Google Scholar
• Glenner G G. Alzheimer's disease: Its proteins and genes. Cell 1988; 52: 307–308
   PubMed Web of Science ®Google Scholar
• Abraham C R, Selkoe D J, Potter H. The putative role of alpha-1-antitrypsin in the disaggregation of amyloid fibrils. J Int Med 1988; 237: 143–149, Immunochemical identification of the serine protease inhibitor α89 Eriksson S, Janciauskiene S and Merlini G (1995)
   Google Scholar
• Solomon A, Weiss D T, Katrine A A. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845–1851
   PubMed Web of Science ®Google Scholar
• Solomon A, Weiss D T, Pepys M B. Induction in mice of human light-chain-associated amyloidosis. Am J Pathol 1992; 140: 629–637
   PubMed Web of Science ®Google Scholar